CClinicalTrials.gg
CompletedNCT05180643M-PARKUpdated Jun 2, 2026

Mindfulness Meditation (MBSR) and Parkinson's Disease (PD)

An interventional study of Mindfulness-Based Stress Reduction-based program (MBSR). in Parkinson Disease, sponsored by University Hospital, Bordeaux. Completed at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Non-pharmacological therapies become more important in the management of Parkinson's disease (PD). Among these, mindfulness meditation is the subject of high expectations. This intervention, such as the Mindfulness-Based Stress Reduction-based (MBSR) stress reduction program, have shown effects on psychological distress, motor and non-motor disorders, and quality of life. However, the data is still very frail and the conditions for practical use are still very uncertain. The objective of the study is to determine the feasibility of a standardized MBSR program in Parkinsonians patients.

Read the detailed description

Recent interest has developed in non-drug methods in the management of PD, especially for non-motor signs since recent years. Numerous studies have been investigated this issue, particularly in regard to mindfulness meditation approaches. Nowadays, the mindfulness-based stress reduction program (MBSR) is the most studied in medicine ([18]). The MBSR program has been studied in Parkinson's disease in numerous studies ([24], [3], [1], [9]) and the program compliance is reported as variable,from high (80%, [24], [9]) to modest (50%,; [3]), with little data on acceptability. Mindfulness meditation in the management of Parkinson's disease is the subject of high expectations for patients and their caregivers but the scientific literature is still very frail and the conditions for practical use in our country remains still very uncertain. What is the feasibility and acceptability of a standard MBSR-type program? For which type of patients? For which symptom (s)? What are the benefits, constraints and / or adverse effects felt? If a nationwide interventional trial were to be proposed, what would be the primary objective? What would be the ideal design? The MBSR program is a standardized group program (10 to 20 people) over 8 weeks. The program is progressive and structured, essentially practical, participatory and interactive, encouraging and supportive. The MBSR program will be supplemented by two visits (1 month before and 1 month later) including: a global clinical evaluation (MDS-UPDRS), a cognitive evaluation (MOCA and TAP battery), depression (BDI-II) and anxiety scales (PAS, self-questionnaire), sleep (Pittsburgh Sleep Quality Index), pain (EVA) and quality of life (PDQ-39). In addition, a qualitative interview on the expectations of the program will be carried during the pre-program interview and a qualitative descriptive evaluation on the acceptability, the adverse effects and the feeling of the program during the post-program interview.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson
  • MBSR
  • Mindfulness
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 31 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient diagnosed with Parkinson's disease
  • Aged over 18
  • Under 80 years old
  • Patient without fluctuation or with minor to moderate motor fluctuations (rated 0 or 3 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)
  • Patient with Hoehn Stadium and Yahr from 1 to 3
  • Patient not presenting with acute depression not stabilized by the treatment or during the last 6 months
  • Patient without unstable psycho-behavioral disorders (hallucinations, psychoses, impulse control disorders) less than 6 months
  • Patient affiliated or beneficiary of the social security scheme
  • Free, informed and written consent (at the latest on the day of inclusion and before any research required by the research).

Exclusion criteria

Exclusion Criteria:

  • Patient with Hoehn Stadium and Yahr over 3
  • Patient with major cognitive impairment (MOCA \<24)
  • Patient with severe motor fluctuation (rated> 3 for all 5 items on the dyskinesia MDS-UPDRS scale and Motor Fluctuations)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    non-fluctuating patients or with minor fluctuations (Group A)

    Patient without fluctuation or with minor motor fluctuations (rated 0 or 1 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)

    Behavioral: Mindfulness-Based Stress Reduction-based program (MBSR).

  • Experimental
    patients with mild to moderate fluctuations (Group B).

    Patient without fluctuation or with minor to moderate motor fluctuations (rated 2 or 3 on all 5 items of the UPDRS-dyskinesia and Motor Fluctuations scale)

    Behavioral: Mindfulness-Based Stress Reduction-based program (MBSR).

Interventions

  • BehavioralMindfulness-Based Stress Reduction-based program (MBSR).

    The MBSR program is built over 8 weeks (1 information session, 8 group sessions from 2h30 to 3h and 1 full day). A trained MBSR instructor will lead group sessions weekly for approximately 150-210 minutes to teach and demonstrate the practices. Practices include walking/standing/supine meditation, body scanning (drawing attention to various areas of the body such as the right foot or left hand), and simple hatha yoga postures. Exercises are the basis of this group learning with practice time and practice exchange time. Participants are asked to commit to daily meditation at home using audioguides for 40 minutes to 1 hour.

06

What researchers measure

Primary outcomes

  1. the rate of patients who completed the entire MBSR program

    the rate of patients who completed the meditation sessions, the full meditation day, and one-to-one daily compliance rate

    Time frame: 6 months after inclusion

Secondary outcomes

  1. Achievement of the MBSR (Mindfulness Based Stress Reduction) program from individual pre-program interview

    Failure factors, problems encountered determined from a individual pre-program interview lasting about 20 minutes for achievement of the MBSR program request

    Time frame: the pre-program interview will be performed 2 months after inclusion (one month before the MBSR program's beginning)

  2. Achievement of the MBSR (Mindfulness Based Stress Reduction) program from individual post-program interview

    Failure factors, problems encountered determined from a individual post-program interview lasting about 20 minutes for achievement of the MBSR program request

    Time frame: the post-program interview will be performed 6 months after inclusion (one month after the end MBSR program)

  3. Acceptability of the MBSR (Mindfulness Based Stress Reduction) program from individual pre-program interview

    Program compliance for collective and individual meditations determined from a individual pre-program interview lasting about 20 minutes for acceptability of the MBSR program request

    Time frame: the pre-program interview will be performed 2 months after inclusion ( one month before the MBSR program's beginning) and will last about one hour in total

  4. Acceptability of the MBSR (Mindfulness Based Stress Reduction) program from individual post-program interview

    Program compliance for collective and individual meditations determined from a individual post-program interview lasting about 20 minutes for acceptability of the MBSR program request

    Time frame: the post-program interview will be performed 6 months after inclusion (one month after the end MBSR program)

  5. Expectations with regard to the MBSR (Mindfulness Based Stress Reduction) program determined from individual pre-program interview

    Patient feelings, impressions and attitudes towards the program determined from a individual pre-program interview lasting about 20 minutes for expectations with regard to the MBSR program request

    Time frame: the pre-program interview will be performed 2 months after inclusion ( one month before the MBSR program's beginning)

  6. Expectations with regard to the MBSR (Mindfulness Based Stress Reduction)program determined from individual post-program interview

    Patient feelings, impressions and attitudes towards the program determined from a individual post-program interview lasting about 20 minutes for the request on expectations with regard to the MBSR program

    Time frame: the post-program interview will be performed 6 months after inclusion ( one month after the MBSR program's beginning)

  7. Motor and non-motor symptoms evaluated by the MDS-UPDRS (Unified Parkison's Disease Ratinf Scale) score at the inclusion

    The MDS-UPDRS score is based on the "Unified Parkinson's Disease Rating Scale" : the MDS-UPDRS makes it possible to assess the different motor and non-motor symptoms. The MDS-UPDRS has four parts: Non-motor experiences of daily life (13 questions); Motor experiences of daily life (13 questions); Motor exam (18 items); Motor complications (6 items). All items are scored from 0 to 4 and are clearly defined: 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe. The duration of the exam is 10 minutes.

    Time frame: at enrollment

  8. Motor and non-motor symptoms evaluated by the MDS-UPDRS (Unified Parkison's Disease Ratinf Scale) score at the end of the following period

    The MDS-UPDRS score is based on the "Unified Parkinson's Disease Rating Scale": The MDS-UPDRS has four parts: Non-motor experiences of daily life (13 questions); Motor experiences of daily life (13 questions); Motor exam (18 items); Motor complications (6 items). All items are scored from 0 to 4 and are clearly defined: 0: normal, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe. The duration of the exam is 10 minutes.

    Time frame: at the end of the following period ( i.e. 6 months after the inclusion, 1 month after the end of the MBSR program

  9. Cognitive efficiency evaluated by the "Montreal Cognitive Assessment" (MOCA) at the inclusion

    The "Montreal Cognitive Assessment" (MoCA, \[23\]). The MoCA assesses mild cognitive dysfunctions. It assesses the following functions: short-term memory, visual spatial skills, executive functions, attention, concentration, working memory, language, abstraction skills, calculation and orientation in the time and space. Cognitive impairment is assessed in terms of the score on 30 points (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; \<10: severe). The duration of the test is 20 minutes.

    Time frame: at enrollment

  10. Cognitive efficiency evaluated by the "Montreal Cognitive Assessment" (MOCA) at the end of the following period

    The "Montreal Cognitive Assessment" (MoCA, \[23\]). The MoCA assesses mild cognitive dysfunctions. It assesses the following functions: short-term memory, visual spatial skills, executive functions, attention, concentration, working memory, language, abstraction skills, calculation and orientation in the time and space. Cognitive impairment is assessed in terms of the score on 30 points (27-30: no cognitive impairment; 18-26: mild; 10-17: moderate; \<10: severe). The duration of the test is 20 minutes.

    Time frame: at the end of the following period ( i.e. 6 months after the inclusion, 1 month after the end of the MBSR program

  11. subjective quality of sleep evaluated by the " Pittsburgh Sleep Quality Index " at the inclusion

    This is a self-questionnaire that assesses the subjective quality of sleep in the past month. It includes 19 questions used to calculate 7 components: subjective quality of sleep, sleep latency, sleep duration, sleep efficiency, sleep disturbance, sleep medication, disturbances in daytime functioning. The overall score is obtained by summing the seven components. It ranges from 0: "no difficulty" to 21: "major difficulties".

    Time frame: at enrollment

  12. subjective quality of sleep evaluated by the " Pittsburgh Sleep Quality Index " at the end of the following period

    This is a self-questionnaire that assesses the subjective quality of sleep in the past month. It includes 19 questions used to calculate 7 components: subjective quality of sleep, sleep latency, sleep duration, sleep efficiency, sleep disturbance, sleep medication, disturbances in daytime functioning. The overall score is obtained by summing the seven components. It ranges from 0: "no difficulty" to 21: "major difficulties".

    Time frame: at enrollment

  13. Attentional functions evaluated by the "Test for Attentional Performance" battery (TAP, Zimmerman & Fimm, 2010) at inclusion

    It is a test evaluating the attentional functions (phasic alert, divided attention, sustained attention, visual scanning, intermodal comparison, displacement of the attentional focus, exploration of the visual field / neglect, flexibility, go / nogo, incompatibility, memory of work, eye motility, alertness).

    Time frame: at enrollment

  14. Attentional functions evaluated by the "Test for Attentional Performance" battery (TAP, Zimmerman & Fimm, 2010) at the end of the following period

    It is a test evaluating the attentional functions (phasic alert, divided attention, sustained attention, visual scanning, intermodal comparison, displacement of the attentional focus, exploration of the visual field / neglect, flexibility, go / nogo, incompatibility, memory of work, eye motility, alertness). The duration of the test is 60 minutes.

    Time frame: at the end of the following period ( i.e. 6 months after the inclusion, 1 month after the end of the MBSR program)

  15. Pain evaluated by the Visual Analog Pain Scale (VAS): at the inclusion

    It is a pain self-assessment scale that allows the patient to self-assess the pain experienced by means of a cursor. A slider allows the patient to self-assess the pain felt by means of a cursor. On the front of the slide, a line or pyramid is drawn on which the patient moves the cursor from the "no pain" end to the "maximum pain imaginable" end. On the back of the slide, the caregiver reads the pain felt by the patient using a scale in millimeters (from 0 to 100 mm). Rating is pain absent: 0, mild pain: 1 to 3, moderate pain: 4 to 6, severe pain: 7 to 9, extremely intense pain: 10.

    Time frame: at the inclusion visit

  16. Pain evaluated by the Visual Analog Pain Scale (VAS): at the end of the following period

    It is a pain self-assessment scale that allows the patient to self-assess the pain experienced by means of a cursor. A slider allows the patient to self-assess the pain felt by means of a cursor. On the front of the slide, a line or pyramid is drawn on which the patient moves the cursor from the "no pain" end to the "maximum pain imaginable" end. On the back of the slide, the caregiver reads the pain felt by the patient using a scale in millimeters (from 0 to 100 mm). Rating is pain absent: 0, mild pain: 1 to 3, moderate pain: 4 to 6, severe pain: 7 to 9, extremely intense pain: 10.

    Time frame: at the end of the following period ( i.e. 6 months after the inclusion, 1 month after the end of the MBSR program

  17. Quality of life evaluated by the " Parkinson Disease Quotation " (PDQ-39) at the inclusion

    It is a self-questionnaire in 39 items assessing the quality of life of Parkinson's patients from a motor and psychological point of view, according to the past month. Each question is scored from 0 (no disturbance) to 4 (maximum disturbance). The items are divided into 8 dimensions (activity of daily life, emotional well-being, psychological discomfort, social support, cognitive disorders, communication, physical discomfort, mobility).

    Time frame: at enrollment

  18. Quality of life evaluated by the " Parkinson Disease Quotation " (PDQ-39) at the end of the following period

    It is a self-questionnaire in 39 items assessing the quality of life of Parkinson's patients from a motor and psychological point of view, according to the past month. Each question is scored from 0 (no disturbance) to 4 (maximum disturbance). The items are divided into 8 dimensions (activity of daily life, emotional well-being, psychological discomfort, social support, cognitive disorders, communication, physical discomfort, mobility).

    Time frame: at the end of the following period ( i.e. 6 months after the inclusion, 1 month after the end of the MBSR program

  19. Anxiety evaluated by the " Parkinson Anxiety Scale " (PAS) at the inclusion

    It is a self-questionnaire evaluating anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items) . Each item is rated from 0 (not at all) to 4 (strongly or almost always). The filling time is 5 minutes.

    Time frame: at enrollment

  20. Anxiety evaluated by the " Parkinson Anxiety Scale " (PAS) at the end of the following period

    It is a self-questionnaire evaluating anxiety in Parkinson's disease dealing with several dimensions of anxiety: Persistent anxiety (5 items), Episodic anxiety (4 items), Avoidance behavior (3 items) . Each item is rated from 0 (not at all) to 4 (strongly or almost always). The filling time is 5 minutes.

    Time frame: at the end of the following period ( i.e. 6 months after the inclusion, 1 month after the end of the MBSR program

07

Study locations

1 site
  • François TISON, M.D PhD
    Bordeaux, 33000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05180643
Lead sponsor
University Hospital, Bordeaux
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Feb 17, 2020
Primary completion
Aug 17, 2021
Completion
Nov 23, 2021
Last update
Jun 2, 2026

Study contacts

François TISON, M.D PhD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion